Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder

Journal of Clinical Psychiatry

Volumn 78, Issue 8, 2017, Pages 1068-1074

  Vande Voort, Jennifer L ^a,b   Ballard, Elizabeth D ^b   Luckenbaugh, David A ^b   Bernert, Rebecca A ^c   Richards, Erica M ^b   Niciu, Mark J ^b   Park, Lawrence T ^b   Machado Vieira, Rodrigo ^b   Duncan, Wallace C ^b   Zarate, Carlos A ^b  

^a MAYO CLINIC   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DSM-IV; ELECTROENCEPHALOGRAPHY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NIGHT; PRIORITY JOURNAL; SINGLE DRUG DOSE; SLEEP; SUICIDAL IDEATION; WAKEFULNESS; COMPLICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUICIDE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME; WAKEFULNESS;

EID: 85032629845     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10440     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention. Injury Prevention and Control: Data and Statistics (WISQARS). CDC Web site. http://www.cdc.gov/injury/wisqars/fatal-injury-reports.html. 2014. Accessed December 12, 2014.
2. Curtin SC, Warner M, Hedegaard H. Increase in suicide in the United States, 1999-2014. National Center for Health Statistics Data Brief. No. 241. April 2016. http://www.cdc.gov/nchs/data/databriefs/db241.pdf
3. Griffiths JJ, Zarate CA Jr, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med. 2014; 47(Suppl 2): S195-S203.
4. Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry. 2005; 162(5):977-982.
5. US Department of Health and Human Services (HHS). 2012 National Strategy for Suicide Prevention: Goals and Objectives for Action. Washington, DC: Health and Human Services; 2012.
6. Bernert RA, Joiner TE. Sleep disturbances and suicide risk: a review of the literature. Neuropsychiatr Dis Treat. 2007; 3(6):735-743.
7. Bjørngaard JH, Bjerkeset O, Romundstad P, et al. Sleeping problems and suicide in 75, 000 Norwegian adults: a 20 year follow-up of the HUNT I study. Sleep. 2011; 34 (9):1155-1159.
8. Pigeon WR, Pinquart M, Conner K. Metaanalysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry. 2012; 73 (9): e1160-e1167.
9. Wong MM, Brower KJ. The prospective relationship between sleep problems and suicidal behavior in the National Longitudinal Study of Adolescent Health. J Psychiatr Res. 2012; 46(7):953-959.
10. Bernert RA, Turvey CL, Conwell Y, et al. Association of poor subjective sleep quality with risk for death by suicide during a 10-year period: a longitudinal, population-based study of late life. JAMA Psychiatry. 2014; 71 (10):1129-1137.
11. Blasco-Fontecilla H, Alegria AA, Lopez-Castroman J, et al. Short self-reported sleep duration and suicidal behavior: a cross-sectional study. J Affect Disord. 2011; 133 (1-2): 239-246.
12. Wojnar M, Ilgen MA, Wojnar J, et al. Sleep problems and suicidality in the National Comorbidity Survey Replication. J Psychiatr Res. 2009; 43(5):526-531.
13. Dahl RE, Puig-Antich J, Ryan ND, et al. EEG sleep in adolescents with major depression: the role of suicidality and inpatient status. J Affect Disord. 1990; 19 (1): 63-75.
14. Duncan WC Jr. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther. 1996; 71(3):253-312.
15. Armitage R, Yonkers K, Cole D, et al. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol. 1997; 17(3):161-168.
16. Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry. 1997; 58 (5):185-192.
17. Kupfer DJ, Perel JM, Pollock BG, et al. Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry. 1991; 29 (1): 23-40.
18. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep qualit y. Neuro psycho biology. 2000; 42(2):69-81.
19. Jindal RD, Friedman ES, Berman SR, et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol. 2003; 23(6): 540-548.
20. van Bemmel AL, van den Hoofdakker RH, Beersma DG, et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology (Berl). 1993; 113(2): 225-230.
21. Roth T, Zorick F, Wittig R, et al. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry. 1982; 43(9): 366-368.
22. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010; 71(12):1605-1611.
23. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiet y. 2014; 31(4): 335-343.
24. Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014; 58:161-166.
25. Ballard ED, Vande Voort JL, Bernert RA, et al. Nocturnal wakefulness is associated with next-day suicidal ideation in major depressive disorder and bipolar disorder. J Clin Psychiatry. 2016; 77(6):825-831.
26. Perlis ML, Grandner MA, Brown GK, et al. Nocturnal wakefulness as a previously unrecognized risk factor for suicide. J Clin Psychiatry. 2016; 77(6): e726-e733.
27. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67(8):793-802.
28. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012; 37(6):1526-1533.
29. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012; 71(11): 939-946.
30. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-864.
31. Duncan WC, Sarasso S, Ferrarelli F, et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013; 16 (2): 301-311.
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-389.
33. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979; 47(2):343-352.
34. Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015; 68:68-73.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
36. Brown GK A Review of Suicide Assessment Measures for Intervention Research With Adults and Older Adults. National Institute of Mental Health; 2000.
37. Weitz E, Hollon SD, Kerkhof A, et al. Do depression treatments reduce suicidal ideation? the effects of CBT, IPT, pharmacotherapy, and placebo on suicidality. J Affect Disord. 2014; 167: 98-103.
38. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Ps ychiatr y. 2008; 63(4): 349-352.
39. Ballard ED, Lally N, Nugent AC, et al. Neural correlates of suicidal ideation and its reduction in depression. Int J Neuropsychopharmacol. 2014; 18 (1): pyu069.
40. Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015; 43: 110-117.
41. Erhardt S, Lim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacolo gy. 2013; 38(5):743-752.
42. Burgos I, Richter L, Klein T, et al. Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study. Brain Behav Immun. 2006; 20(3):246-253.
43. Zai CC, Manchia M, De Luca V, et al. The brain-derived neurotrophic factor gene in suicidal behaviour: a meta-analysis. Int J Neuropsychopharmacol. 2012; 15(8):1037-1042.
44. Kim YK, Lee HP, Won SD, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(1):78-85.
45. Haile CN, Murrough JW, Iosifescu DV, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014; 17 (2): 331-336.
46. Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012; 72(11): e27-e28.
47. Grunebaum MF, Galfalvy HC, Oquendo MA, et al. Melancholia and the probability and lethality of suicide attempts. Br J Psychiatry. 2004; 184: 534-535.